Observational Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Mar 6, 2021; 9(7): 1619-1630
Published online Mar 6, 2021. doi: 10.12998/wjcc.v9.i7.1619
Figure 1
Figure 1 Plasma soluble 4-1BB levels in various groups of treatment-naïve patients with chronic hepatitis B (except for the comparison between treatment naïve group and entecavir treated group). A: Soluble 4-1BB (s4-1BB) levels in healthy adults and chronic hepatitis B (CHB); B and C: s4-1BB levels in patients with CHB in various phases of disease (CHB flare means infection exhibiting a disease flare up, elevated alanine aminotransferase; CHB inactive means patients with inactive disease, normal alanine aminotransferase); D: s4-1BB levels before and after treatment in patients with hepatitis B virus; E: Plasma s4-1BB levels in healthy adults and healthy children; F: Plasma s4-1BB levels in healthy male donors and healthy female donors. P values were obtained by the Mann–Whitney U test or unpaired t test according to the characteristics of the data. cP < 0.001 vs healthy adult group; dP < 0.05 vs chronic hepatitis B inactive group; eP < 0.05 vs log10HBV DNA < 5 group. CHB: Chronic hepatitis B; s4-1BB: Soluble 4-1BB; ETV: Entecavir.